| German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients K Rahbar, H Ahmadzadehfar, C Kratochwil, U Haberkorn, M Schäfers, ... Journal of Nuclear Medicine 58 (1), 85-90, 2017 | 915 | 2017 |
| Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In-or 68Ga-labeled affibody molecules RP Baum, V Prasad, D Müller, C Schuchardt, A Orlova, A Wennborg, ... Journal of nuclear medicine 51 (6), 892-897, 2010 | 363 | 2010 |
| Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68Ga-DOTA-NOC receptor PET/CT V Prasad, V Ambrosini, M Hommann, D Hoersch, S Fanti, RP Baum European journal of nuclear medicine and molecular imaging 37, 67-77, 2010 | 307 | 2010 |
| Molecular imaging with 68Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours D Kaemmerer, L Peter, A Lupp, S Schulz, J Sänger, V Prasad, H Kulkarni, ... European journal of nuclear medicine and molecular imaging 38, 1659-1668, 2011 | 178 | 2011 |
| Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors D Kaemmerer, L Peter, A Lupp, S Schulz, J Sänger, RP Baum, V Prasad, ... International journal of clinical and experimental pathology 5 (3), 187, 2012 | 177 | 2012 |
| Immunohistochemical validation of PSMA expression measured by 68Ga-PSMA PET/CT in primary prostate cancer N Woythal, R Arsenic, C Kempkensteffen, K Miller, JC Janssen, K Huang, ... Journal of Nuclear Medicine 59 (2), 238-243, 2018 | 168 | 2018 |
| Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions V Prasad, RP Baum QJ Nucl Med Mol Imaging 54 (1), 61-67, 2010 | 162 | 2010 |
| Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms RP Baum, HR Kulkarni, A Singh, D Kaemmerer, D Mueller, V Prasad, ... Oncotarget 9 (24), 16932, 2018 | 145 | 2018 |
| 2017 GPOH guidelines for diagnosis and treatment of patients with neuroblastic tumors T Simon, B Hero, JH Schulte, H Deubzer, P Hundsdoerfer, ... Klinische Pädiatrie 229 (03), 147-167, 2017 | 142 | 2017 |
| Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours LM Dilz, T Denecke, IG Steffen, V Prasad, LF Von Weikersthal, UF Pape, ... European Journal of Cancer 51 (10), 1253-1262, 2015 | 140 | 2015 |
| PET/CT imaging of osteoblastic bone metastases with 68Ga-bisphosphonates: first human study M Fellner, RP Baum, V Kubíček, P Hermann, I Lukeš, V Prasad, F Rösch European Journal of Nuclear Medicine and Molecular Imaging 37, 834-834, 2010 | 140 | 2010 |
| The status of neuroendocrine tumor imaging: from darkness to light? L Bodei, A Sundin, M Kidd, V Prasad, IM Modlin Neuroendocrinology 101 (1), 1-17, 2015 | 128 | 2015 |
| Biodistribution of [68Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions V Prasad, IG Steffen, G Diederichs, MR Makowski, P Wust, W Brenner Molecular imaging and biology 18, 428-436, 2016 | 125 | 2016 |
| A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management K Oberg, E Krenning, A Sundin, L Bodei, M Kidd, M Tesselaar, ... Endocrine connections 5 (5), 174-187, 2016 | 123 | 2016 |
| NET blood transcript analysis defines the crossing of the clinical rubicon: when stable disease becomes progressive M Pavel, H Jann, V Prasad, I Drozdov, IM Modlin, M Kidd Neuroendocrinology 104 (2), 170-182, 2016 | 120 | 2016 |
| Child–Pugh Classification: Time to Abandon? B Kok, JG Abraldes Seminars in liver disease 39 (01), 096-103, 2019 | 113 | 2019 |
| European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes J Hofland, M Falconi, E Christ, JP Castaño, A Faggiano, A Lamarca, ... Journal of neuroendocrinology 35 (8), e13318, 2023 | 108 | 2023 |
| 177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer WP Fendler, C Kratochwil, H Ahmadzadehfar, K Rahbar, RP Baum, ... Nuklearmedizin. Nuclear Medicine 55 (3), 123-128, 2016 | 106 | 2016 |
| European Neuroendocrine Tumor Society (ENETS) 2022 guidance paper for carcinoid syndrome and carcinoid heart disease S Grozinsky‐Glasberg, J Davar, J Hofland, R Dobson, V Prasad, ... Journal of neuroendocrinology 34 (7), e13146, 2022 | 105 | 2022 |
| Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor D Kaemmerer, V Prasad, W Daffner, D Hörsch, G Klöppel, M Hommann, ... World journal of gastroenterology: WJG 15 (46), 5867, 2009 | 104 | 2009 |
